Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.7400+0.0100 (+0.58%)
At close: 04:00PM EST
1.7300 -0.01 (-0.57%)
After hours: 07:22PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7300
Open1.7200
Bid1.7300 x 1300
Ask1.7500 x 1800
Day's Range1.6700 - 1.7500
52 Week Range1.6700 - 9.6700
Volume333,724
Avg. Volume614,453
Market Cap74.583M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

    Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of r

  • GlobeNewswire

    AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, and Susan Schneider M.D., Chief Medical Office

  • GlobeNewswire

    AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

    Robinson’s expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management teamGAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited re

Advertisement
Advertisement